01 1Cipla
01 1SALMETEROL XINAFOATE USP
01 1India
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2020-01-28
Pay. Date : 2019-12-12
DMF Number : 34335
Submission : 2019-12-17
Status : Active
Type : II
20
Cipla Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is SALMETEROL XINAFOATE USP, with a corresponding US DMF Number 34335.
Remarkably, this DMF maintains an Active status since its submission on December 17, 2019, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of January 28, 2020, and payment made on December 12, 2019, indicating their dedication to facilitating drug approvals, Categorized as Type II
